Regeneron Pharmaceuticals' Gains from Investment Securities fell 103.99% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.3 million, marking a year-over-year decrease of 81.03%. This contributed to the annual value of $1.0 billion for FY2024, which is 18.25% up from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Gains from Investment Securities of $1.0 billion as of FY2024, which was up 18.25% from $870.3 million recorded in FY2023.
Over the past 5 years, Regeneron Pharmaceuticals' Gains from Investment Securities peaked at $1.5 billion during FY2022, and registered a low of $680.8 million during FY2020.
In the last 3 years, Regeneron Pharmaceuticals' Gains from Investment Securities had a median value of $1.0 billion in 2024 and averaged $1.1 billion.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Gains from Investment Securities soared by 98.89% in 2020, and later crashed by 42.07% in 2023.
Over the past 5 years, Regeneron Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $680.8 million in 2020, then soared by 78.97% to $1.2 billion in 2021, then grew by 23.31% to $1.5 billion in 2022, then tumbled by 42.07% to $870.3 million in 2023, then rose by 18.25% to $1.0 billion in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value